Halozyme Therapeutics, Inc. (NASDAQ:HALO) Shares Sold by Ameritas Investment Partners Inc.

Ameritas Investment Partners Inc. reduced its position in Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 7.1% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 39,293 shares of the biopharmaceutical company’s stock after selling 2,989 shares during the period. Ameritas Investment Partners Inc.’s holdings in Halozyme Therapeutics were worth $2,057,000 at the end of the most recent reporting period.

Several other institutional investors also recently bought and sold shares of the business. TD Asset Management Inc grew its position in shares of Halozyme Therapeutics by 517.0% in the fourth quarter. TD Asset Management Inc now owns 1,983,916 shares of the biopharmaceutical company’s stock valued at $73,326,000 after purchasing an additional 1,662,390 shares during the period. Norges Bank purchased a new stake in Halozyme Therapeutics in the 4th quarter valued at about $44,935,000. Epoch Investment Partners Inc. increased its stake in shares of Halozyme Therapeutics by 250.5% during the 4th quarter. Epoch Investment Partners Inc. now owns 1,163,033 shares of the biopharmaceutical company’s stock valued at $42,986,000 after acquiring an additional 831,199 shares during the last quarter. Boston Trust Walden Corp purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter worth about $23,211,000. Finally, Swedbank AB acquired a new stake in shares of Halozyme Therapeutics in the first quarter worth approximately $13,927,000. 97.79% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

HALO has been the topic of a number of recent analyst reports. TD Cowen increased their price target on shares of Halozyme Therapeutics from $59.00 to $65.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Morgan Stanley increased their target price on Halozyme Therapeutics from $59.00 to $64.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 7th. Benchmark reissued a “buy” rating and set a $60.00 price target on shares of Halozyme Therapeutics in a research report on Thursday, August 8th. JPMorgan Chase & Co. lowered Halozyme Therapeutics from an “overweight” rating to a “neutral” rating and upped their price target for the stock from $52.00 to $57.00 in a research note on Thursday. Finally, Wells Fargo & Company lifted their price objective on Halozyme Therapeutics from $48.00 to $58.00 and gave the company an “overweight” rating in a research note on Friday, June 7th. Three research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $60.00.

Halozyme Therapeutics Stock Performance

Halozyme Therapeutics stock opened at $59.24 on Friday. The firm has a market capitalization of $7.54 billion, a PE ratio of 24.48, a price-to-earnings-growth ratio of 0.57 and a beta of 1.28. Halozyme Therapeutics, Inc. has a one year low of $32.83 and a one year high of $65.53. The stock’s 50 day moving average price is $58.40 and its 200 day moving average price is $49.20. The company has a debt-to-equity ratio of 5.19, a quick ratio of 6.21 and a current ratio of 7.41.

Halozyme Therapeutics (NASDAQ:HALO) last announced its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.91 earnings per share for the quarter, beating the consensus estimate of $0.73 by $0.18. Halozyme Therapeutics had a net margin of 38.62% and a return on equity of 195.80%. The business had revenue of $231.40 million during the quarter, compared to the consensus estimate of $204.94 million. During the same period in the prior year, the firm earned $0.68 earnings per share. The business’s quarterly revenue was up 4.7% compared to the same quarter last year. As a group, sell-side analysts expect that Halozyme Therapeutics, Inc. will post 3.7 EPS for the current fiscal year.

Insider Activity

In related news, CFO Nicole Labrosse sold 10,000 shares of the business’s stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $51.93, for a total value of $519,300.00. Following the transaction, the chief financial officer now owns 15,480 shares in the company, valued at $803,876.40. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other Halozyme Therapeutics news, CFO Nicole Labrosse sold 10,000 shares of Halozyme Therapeutics stock in a transaction that occurred on Thursday, June 27th. The stock was sold at an average price of $51.93, for a total transaction of $519,300.00. Following the sale, the chief financial officer now directly owns 15,480 shares in the company, valued at approximately $803,876.40. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Matthew L. Posard sold 9,881 shares of the stock in a transaction that occurred on Wednesday, August 14th. The shares were sold at an average price of $57.70, for a total value of $570,133.70. Following the transaction, the director now owns 69,874 shares of the company’s stock, valued at $4,031,729.80. The disclosure for this sale can be found here. Insiders sold 84,881 shares of company stock worth $4,888,184 over the last ninety days. Corporate insiders own 2.40% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.